SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...
Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...
Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...
Stocktwits on MSN1d
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors ExpectSpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...
"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...
The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...
A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback